The goal of this clinical trial is to improve the successful healthcare transition from pediatric to adult-focused care for childhood cancer survivors. The main questions it aims to answer are
* Receipt of the intervention (vs. standard of care control) will increase the proportion of CCS achieving transition success to adult-focused survivorship care from 50% to 70%. * Receipt of the intervention (vs. standard of care control) will significantly reduce patients' unmet HRSN. * Intervention effectiveness will be moderated by sociodemographic factors (gender, race/ethnicity, insurance status), medical risk for late effects, HRSN burden, and patient-reported outcomes (quality of life, self-efficacy).
Researchers will compare those that receive intervention versus standard of care.
Patients are randomized to either an intervention group, receiving structured PN-led sessions and tailored support for care transitions, or a control group receiving standard follow-up by a nurse case manager. High-HRSN patients in the intervention arm get monthly check-ins and coordinated handoffs to adult care providers for continuity.
diagnosed between the ages of 0-19 years with cancer or with any condition treated with cancer-like therapy.
currently in follow up at survivorship clinic or had a survivorship launch visit during the 12 months prior to study activation.
current age 20-29 (>95% of patients will be age 20-21)
at least 5 years off treatment
do not meet transition criteria
speak a language other than English or Spanish
are significantly impaired and cannot provide informed consent.
Children's Hospital Los Angeles
Lead sponsor
National Cancer Institute (NCI)
Collaborator